Acute Myeloid Leukemia (AML) is a type of blood cancer that originates in the bone marrow — the spongy tissue inside bones where blood cells are produced. In AML, the bone marrow produces abnormal white blood cells (called myeloid blasts) that accumulate rapidly, crowding out normal blood cells and impairing the body's ability to fight infections, carry oxygen, and control bleeding.
AML can develop at any age but is more common in adults over 60. Symptoms often appear suddenly and may include persistent fatigue, frequent infections, unexplained bruising or bleeding, shortness of breath, bone or joint pain, and unintentional weight loss. Because these symptoms overlap with many common conditions, AML is sometimes discovered incidentally through routine blood work.
Diagnosis begins with a Complete Blood Count (CBC) that may show abnormal WBC counts, low hemoglobin, or low platelets. A peripheral blood smear examined under the microscope can reveal circulating blast cells. However, a bone marrow biopsy is essential for confirming the diagnosis — it shows the percentage of blasts and provides material for further testing.
Modern AML diagnosis goes far beyond morphology. Immunophenotyping by flow cytometry identifies the specific surface markers on leukemic cells, helping classify the AML subtype. Cytogenetic analysis looks for chromosomal abnormalities that have prognostic significance — for example, t(8;21) and inv(16) are associated with favorable outcomes, while complex karyotypes often indicate aggressive disease.
Molecular testing has transformed AML management. Mutations in genes like FLT3, NPM1, CEBPA, IDH1, IDH2, and TP53 influence prognosis and treatment decisions. FLT3-ITD mutations, for instance, are associated with higher relapse risk but can now be targeted with specific inhibitors. NPM1 mutations without FLT3 are generally favorable. This molecular profiling is now considered standard of care.
JAK2 mutations, while more commonly associated with myeloproliferative neoplasms, can also occur in AML and carry clinical significance. Research into composite mutations — where multiple driver gene mutations co-exist in the same patient — is revealing new patterns that affect treatment response and outcomes.
Treatment for AML typically involves intensive chemotherapy in two phases: induction (to achieve remission) and consolidation (to prevent relapse). Younger, fit patients may be candidates for stem cell transplantation. Targeted therapies based on molecular profiling are increasingly available and are changing the treatment landscape.
If you or a loved one has been diagnosed with AML, understanding your specific subtype and molecular profile is crucial. A second opinion on your pathology and molecular results can help ensure accurate classification and optimal treatment planning.